{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:15:28Z","timestamp":1794320128633,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013098","name":"Scientific and Innovative Action Plan of Shanghai","doi-asserted-by":"publisher","award":["21Y31920300"],"award-info":[{"award-number":["21Y31920300"]}],"id":[{"id":"10.13039\/501100013098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn &amp; Yahr stages, patients are often divided into mild\/early stage, moderate\/middle stage, and advanced\/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works, we found that during the early stage, the main syndrome is Yin deficiency of the liver and kidney; during the moderate stage, the main syndromes are phlegm heat and wind stirring and blood stasis and wind stirring; and during the late stage, the dominant syndromes are deficiency of Yin and Yang and deficiency of Qi and blood. Hence, we proposed a new model of TCM treatment by the stage of PD. Based on Shudi Pingchan formula, an experimental formula of our team, we developed Ziyin Pingchan formula, Jiedu Pingchan formula, and Fuzheng Pingchan formula to treat each stage. This study is designed to evaluate the therapeutic effect of treating Parkinson\u2019s disease by stages using traditional Chinese medicine and to provide an evidence base for forming a standardized scheme of diagnosis and treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is designed as a multicentre, randomized, double-blind, placebo-controlled clinical trial. Patients will be stratified into 3 subgroups according to Hoehn &amp; Yahr stage; 172, 168, and 72 participants will be required to be in the mild PD, moderate PD, and advanced PD subgroups, respectively, and will be randomized into the treatment or control group at a 1:1 ratio. The mild PD subgroup will receive a 48-week intervention, and the other 2 groups will receive a 24-week intervention. All groups will have a follow-up visit 12\u00a0weeks after starting the intervention. The intervention group will receive the Ziyin Pingchan formula, Jiedu Pingchan formula, or Fuzheng Pingchan formula, and the control group will receive the corresponding placebo. The primary outcomes will be the first addition of levodopa for the mild PD subgroup, the duration of the \u201cOFF\u201d period for the moderate PD subgroup, and the Parkinson's Disease Questionnaire (PDQ-39) for the advanced PD subgroup. The secondary outcomes will also be verified by subgroups, including the Unified Parkinson\u2019s Disease Rating Scale (UPDRS), Parkinson\u2019s Disease Sleep Scale-2 (PDSS-2), scales for Outcomes in Parkinson\u2019s Disease\u2014Autonomic (SCOPA-AUT), and the nonmotor symptom scale (NMSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Expected outcomes<\/jats:title><jats:p>To our knowledge, this is the first trial to combine TCM syndrome differentiation with PD clinical stages and put it into clinical practice. The results of this trial will provide clinical evidence for the therapeutic effect of TCM formulas on PD patients of all stages and help build a new TCM treatment by stage model of PD.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>: This trial is registered at the Chinese Clinical Trial Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/\">http:\/\/www.chictr.org.cn\/<\/jats:ext-link>). Registration number: ChiCTR2200056373, Date: 2022\u201302-04, version 1.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13020-022-00625-4","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T10:05:43Z","timestamp":1655114743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson\u2019s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Yuqing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sichun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canxing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"6","key":"625_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LML de Lau","year":"2006","unstructured":"de Lau LML, Breteler MMB. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5(6):525\u201335.","journal-title":"Lancet Neurol"},{"issue":"8","key":"625_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson\u2019s disease. J Neural Transm. 2017;124(8):901\u20135.","journal-title":"J Neural Transm"},{"issue":"s1","key":"625_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3\u20138.","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"625_CR4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/mds.27447","volume":"33","author":"M Wanneveich","year":"2018","unstructured":"Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P. Projections of prevalence, lifetime risk, and life expectancy of Parkinson\u2019s disease (2010\u20132030) in France. Mov Disord. 2018;33(9):1449\u201355.","journal-title":"Mov Disord"},{"issue":"5","key":"625_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"issue":"4","key":"625_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mdc3.12476","volume":"4","author":"M Skorvanek","year":"2017","unstructured":"Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol J-C, Taba P, et al. Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration. Mov Disord Clin Pract. 2017;4(4):536\u201344.","journal-title":"Mov Disord Clin Pract"},{"issue":"9","key":"625_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"625_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","volume":"20","author":"J Yuan","year":"2019","unstructured":"Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20(1):19\u201333.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"625_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"625_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548\u201360.","journal-title":"JAMA"},{"issue":"4","key":"625_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/1871527316666170124165222","volume":"16","author":"L Dezsi","year":"2017","unstructured":"Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets. 2017;16(4):425\u201339.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"7","key":"625_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJM196702162760703","volume":"276","author":"GC Cotzias","year":"1967","unstructured":"Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276(7):374\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"625_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/ene.12751","volume":"23","author":"NW Scott","year":"2016","unstructured":"Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson\u2019s disease cohort. Eur J Neurol. 2016;23(2):304\u201312.","journal-title":"Eur J Neurol"},{"issue":"6","key":"625_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","volume":"84","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, et al. Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol. 2018;84(6):797\u2013811.","journal-title":"Ann Neurol"},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"728083","DOI":"10.3389\/fnins.2021.728083","volume":"15","author":"X Ruan","year":"2021","unstructured":"Ruan X, Lin F, Wu D, Chen L, Weng H, Yu J, et al. Comparative efficacy and safety of dopamine agonists in advanced Parkinson\u2019s disease with motor fluctuations: a systematic review and network meta-analysis of double-blind randomized controlled trials. Front Neurosci. 2021;15:728083.","journal-title":"Front Neurosci"},{"key":"625_CR16","doi-asserted-by":"publisher","first-page":"108869","DOI":"10.1016\/j.neuropharm.2021.108869","volume":"204","author":"D Larson","year":"2022","unstructured":"Larson D, Simuni T. New dopaminergic therapies for PD motor complications. Neuropharmacology. 2022;204:108869.","journal-title":"Neuropharmacology"},{"issue":"6","key":"625_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/mds.28599","volume":"36","author":"FAP Nijhuis","year":"2021","unstructured":"Nijhuis FAP, Esselink R, de Bie RMA, Groenewoud H, Bloem BR, Post B, et al. Translating evidence to advanced Parkinson\u2019s disease patients: a systematic review and meta-analysis. Mov Disord. 2021;36(6):1293\u2013307.","journal-title":"Mov Disord"},{"key":"625_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/bs.irn.2017.02.004","volume":"135","author":"B-Y Zeng","year":"2017","unstructured":"Zeng B-Y. Effect and mechanism of Chinese herbal medicine on Parkinson\u2019s disease. Int Rev Neurobiol. 2017;135:57\u201376.","journal-title":"Int Rev Neurobiol"},{"issue":"5","key":"625_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0254-6272(17)30324-2","volume":"37","author":"H Chen","year":"2017","unstructured":"Chen H, Zhang Z, He J, Teng L, Yuan C. Traditional Chinese medicine symptom pattern analysis for Parkinson\u2019s disease. J Tradit Chin Med. 2017;37(5):688\u201394.","journal-title":"J Tradit Chin Med"},{"key":"625_CR20","first-page":"229","volume-title":"New English Version of Essential Questions in Yellow Emperor's Inner Cannon","author":"M-S Yang","year":"2015","unstructured":"Yang M-S. New English Version of Essential Questions in Yellow Emperor's Inner Cannon. Shanghai: Fudan University Press, 2015: 229."},{"issue":"7","key":"625_CR21","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.4103\/1673-5374.235075","volume":"13","author":"Q Ye","year":"2018","unstructured":"Ye Q, Yuan X-L, Yuan C-X, Zhang H-Z, Yang X-M. Zishenpingchan granules for the treatment of Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled clinical trial. Neural Regen Res. 2018;13(7):1269\u201375.","journal-title":"Neural Regen Res"},{"issue":"2","key":"625_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.joim.2020.12.006","volume":"19","author":"SC Gu","year":"2021","unstructured":"Gu SC, Zhou J, Ye Q, Yuan CX. Pingchan granule for depressive symptoms in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. J Integr Med. 2021;19(2):120\u20138.","journal-title":"J Integr Med"},{"issue":"2","key":"625_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0254-6272(17)30051-1","volume":"37","author":"Q Ye","year":"2017","unstructured":"Ye Q, Yuan X, Zhou J, Yuan C, Yang X. Effect of Zishenpingchan granule prepared from Chinese medicinal substances on the c-Jun N-terminal protein kinase pathway in mice with Parkinson\u2019s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Tradit Chin Med. 2017;37(2):244\u201351.","journal-title":"J Tradit Chin Med"},{"issue":"10","key":"625_CR24","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4103\/1673-5374.193242","volume":"11","author":"Q Ye","year":"2016","unstructured":"Ye Q, Yuan X-L, He J, Zhou J, Yuan C-X, Yang X-M. Anti-apoptotic effect of granule in the substantia nigra of rat models of Parkinson\u2019s disease. Neural Regen Res. 2016;11(10):1625\u201332.","journal-title":"Neural Regen Res"},{"key":"625_CR25","doi-asserted-by":"crossref","first-page":"342506","DOI":"10.1155\/2014\/342506","volume":"2014","author":"Q Ye","year":"2014","unstructured":"Ye Q, Yuan X-L, Zhou J, Yuan C-X, Yang X-M. Effect of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias. Evid Based Complement Alternat Med. 2014;2014:342506.","journal-title":"Evid Based Complement Alternat Med"},{"key":"625_CR26","first-page":"9055574","volume":"2021","author":"C-Y Qi","year":"2021","unstructured":"Qi C-Y, Wang J, Wu X, He S-R, Zhang Q, Wu J-H, et al. Botanical, Traditional Use, Phytochemical, and Toxicological of. Evid Based Complement Alternat Med. 2021;2021:9055574.","journal-title":"Evid Based Complement Alternat Med"},{"key":"625_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jep.2017.10.015","volume":"219","author":"Z Fu","year":"2018","unstructured":"Fu Z, Fan X, Wang X, Gao X. Cistanches Herba: an overview of its chemistry, pharmacology, and pharmacokinetics property. J Ethnopharmacol. 2018;219:233\u201347.","journal-title":"J Ethnopharmacol"},{"key":"625_CR28","first-page":"739194","volume":"13","author":"S-C Gu","year":"2022","unstructured":"Gu S-C, Ye Q, Wang C-D, Zhao S-R, Zhou J, Gao C, et al. Pingchan granule for motor symptoms and non-motor symptoms of Parkinson\u2019s disease: a randomized, double-blind. Placebo-Controlled Study Front Pharmacol. 2022;13:739194.","journal-title":"Placebo-Controlled Study Front Pharmacol"},{"key":"625_CR29","volume-title":"Medical statistics","author":"XY Sun Zhenqiu","year":"2014","unstructured":"Sun Zhenqiu XY. Medical statistics. 4th ed. Beijing: People\u2019s Medical Publishing House; 2014.","edition":"4"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-022-00625-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T21:19:55Z","timestamp":1727385595000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-022-00625-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1186\/s13020-022-00625-4","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"12 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This protocol was approved by the Research Ethics Committee of Longhua Hospital Affiliated with the Shanghai University of Traditional Chinese Medicine (2022LCSY002). The study is also registered at the Chinese Clinical Trial Registry (ChiCTR2200056373). All study centres will receive ethical clearances from their ethics committees. Prior to final enrolment, participants will be given a clear explanation of the study details and asked to sign the Informed Consent Form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}